Milestone Pharmaceuticals Inc. (MIST)

1d ago, source: Yahoo Finance

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new clinical ...

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

2d ago, source:

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present ...

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

23d ago, source: Business Insider

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

Charlotte’s Milestone Pharmaceuticals advancing heart drug

10d ago, source: ncbiotech.org

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is back on track with a potential drug to ...

Milestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy Recommendation

29d ago, source: Business Insider

TD Cowen analyst Ritu Baral maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) today and set a price target of $9.00. Ritu Baral has given his Buy rating due to a ...

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split

17h ago, source:

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock ...

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

24d ago, source: Stockhouse

BOSTON,MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones ...

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

7d ago, source:

Zentalis received an upfront payment of $35 million and is eligible to earn up to $275 million in payments after ...

Global Pharmaceutical Drug Delivery Industry is projected to increase at a 6.4% CAGR and cross the US$3.5 Trillion milestone by 2033 | FMI

8d ago, source: Future Market Insights

The Global Pharmaceutical Drug Delivery Industry is on track for significant growth, driven by innovation and increasing ...

Milestone Pharmaceuticals Inc MIST

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

23d ago, source: Finanznachrichten

2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific ...